

# SAFETY & QUALITY OF MEDICINES GROUP

## Meeting

Thursday 20<sup>th</sup> October 2005

Time: 9.30am to 14.30pm

### Attendees

Gillian Bohm (MOH) - Chair  
 Beth Loe (Project Manager)  
 Peter Moodie (PHARMAC)  
 Peter Black (ADHB)  
 Mary Seddon (CMDHB)  
 Jane Vella Brincat (Canterbury)  
 Grant Howard (Waikato)  
 Marilyn Crawley (Waitemata)  
 Adam McRae (PHARMAC)  
 Teresa Sullivan (ACC)  
 Elizabeth Plant (Taranaki)

### Minutes

Item	Topic/agenda	Notes/comments	Action Required
1.	Apologies	Dwayne Crombie, Tim Maling, Emil Schmitt, Avril Lee	
2.	Minutes of meeting 25.8.05	<ul style="list-style-type: none"> <li>Agreed</li> </ul>	
	Introduction	<ul style="list-style-type: none"> <li>Teresa Sullivan the new Patient Safety Team manager at ACC introduced herself, ACC currently have 3 months of data of claims for treatment injury the and 30% of the incidents reported have been adverse drug events</li> </ul>	
3.	Membership of group	<ul style="list-style-type: none"> <li>3 members of PHARMAC's CAC, 4 applicants who responded to previous advert and an applicant who had applied via PHARMAC were all considered</li> <li>College have confirmed their representative as Frances Mc Clure (she has been informed about this via the college) and Jim Vause will attend when Frances is unable to</li> </ul>	<ul style="list-style-type: none"> <li>Letter to successful consumer applicant Sharon Cole (<b>Beth</b>)</li> <li>Add Frances Mc Clure and Jim Vause to the distribution list (<b>Beth</b>)</li> </ul>
4.	Strategy	<ul style="list-style-type: none"> <li>Strategy document at the printers</li> <li>New Minister unable to attend on November 17<sup>th</sup>, and unlikely for December 15<sup>th</sup>, in light of the work we need to do planning for this, leave the minister coming to a meeting until February next year</li> <li>Suggest Dwayne try and meet with the Minister for 30minutes to present the strategy document to him as soon as possible</li> <li>It was agreed to hold the November meeting to further discuss the action plans</li> </ul>	<ul style="list-style-type: none"> <li>Invite Minister to February meeting (<b>Beth, Dwayne</b>)</li> <li>Arrange meeting with Minister in November (<b>Beth, Dwayne</b>)</li> <li>November meeting booked at the Ministry of Health</li> <li>Progress the action plans prior to next meeting (<b>Gillian, Beth</b>)</li> </ul>

		<p>and to meet with interested parties re bar coding</p> <ul style="list-style-type: none"> <li>• The December 15<sup>th</sup> meeting would be held in Auckland at the Grand Chancellor</li> <li>• Discussion about action plans</li> </ul> <p><u>Leadership and National Co-ordination</u> specific objectives:</p> <ol style="list-style-type: none"> <li>1. Extension of committee, accomplished</li> <li>2. Provide advice to Minister of Health; need to add: points about funding ie for secretariat, advisory group and project scoping costs</li> <li>3. Leadership of culture change; need to add <ul style="list-style-type: none"> <li>• levels ie consumer, professional, political</li> <li>• need for national event reporting system?,</li> <li>• involve nursing organisations to change nursing culture</li> <li>• HDC, accreditation and political leadership at national level</li> <li>• Would it benefit to invite Peter Davies to a meeting</li> </ul> </li> <li>4. Development of toolkits; need to add: linking with MOH quality team under aims, action required: high and low level toolkits and need for nominated people in each DHB <ul style="list-style-type: none"> <li>• Discussed report from Waitemata QUM pharmacists about Australian toolkit and suitability for NZ, might be possible for someone from each DHB to obtain a kit free of charge, currently no price available</li> </ul> </li> </ol> <p><u>DHB Participation in Medication Safety</u></p> <ol style="list-style-type: none"> <li>i. Add in to aims: have QUM in strategic plans and so that progress would be reported</li> <li>ii. in annual plans</li> <li>iii. One measure of success: number of hits on website</li> <li>iv. Add to stakeholders direct involvement: Clinical facilitators and kept informed: ACC</li> <li>v. Under action required add QUMap as a central register of projects (different to group website)</li> </ol> <p><u>Best practice prescribing, dispensing and administration</u></p> <ol style="list-style-type: none"> <li>i. See attached sheet</li> </ol> <p><u>High Risk Medicines and High Risk Situations</u> Nothing available: measure of success would be change in practice</p> <p><u>Systems, Processes, Technology and Information Systems</u></p> <ol style="list-style-type: none"> <li>1. Develop &amp; implement National Medicines Chart etc discussion re feasibility and benefit of enforcing national drug chart: would enforce that approx 70% would be standard and</li> </ol>	
--	--	---	--

		<p>remaining DHB specific, benefits shown in Australia with recent trial of paediatric chart and in UK when they introduced a standard drug chart in 70's, need to develop toolkits for introducing standard yellow card, discharge summary etc</p> <p>2. and 4. Common medication record and electronic prescribing system: need to scope a national plan, invite HINZ to meeting</p> <p>3. Barcoding: add in meeting Nov 17<sup>th</sup>  <u>Primary Care and Primary/Secondary interface</u>  i. See attached sheet  <u>Audit, evaluation, monitoring and research</u>  Nothing available</p> <ul style="list-style-type: none"> <li>Discussed audit recently completed at CMDHB based on US audit process looking at how nurses view what would happen if they reported an incident</li> </ul> <p><u>Consumer awareness</u>  Nothing available</p> <ul style="list-style-type: none"> <li>Could base presentation to minister on warfarin: what we have done so far, video, alert and what we would like to do i.e. clinical indicators, flip chart in other languages, toolkit for nurses etc</li> </ul>	
8.	Correspondence		
8.i	Calcium and Vitamin D for people aged over 80yrs in rest homes <b>For information only</b>	<ul style="list-style-type: none"> <li>Group asked by Injury Prevention division of ACC to discuss benefits and risks of the proposal and if there would be anyone at the MOH who might be interested in MOH and ACC pursuing it as a joint venture</li> <li>Discussed various trial reports including some recent ones suggesting that there may be no benefit</li> </ul>	<ul style="list-style-type: none"> <li>Referred to Dilky Rasiah (PHARMAC) for input from MOH perspective</li> </ul>
8.ii	Renal dose calculations	<ul style="list-style-type: none"> <li>Request from Waitemata QUM pharmacist for group to facilitate wider consultation on the development of electronic tools to alert primary care prescribers and pharmacists to adjust doses of renally cleared medicines in patients with renal impairment</li> <li>Discussion around MDRD v Cockcroft and Gault</li> <li>Discussion about the need for a limited list of drugs so that the alerts are not ignored as they often are for drug interactions because there are so many and many are insignificant</li> </ul>	<ul style="list-style-type: none"> <li>Agreed to support the wider consultation</li> <li>Group about to launch strategy document and currently prioritising all projects, could Waitemata QUM pharmacists develop a project plan for consultation (<b>Beth, Waitemata QUM pharmacists</b>)</li> <li>Canterbury offered to help (<b>Jane</b>)</li> </ul>
8.iii	Fentanyl patches	<ul style="list-style-type: none"> <li>Waikato pharmacist asks if the group would consider producing an alert about these for primary care</li> <li>Not used in great numbers because currently not funded</li> <li>Definitely risks identified with their use and disposal</li> </ul>	<ul style="list-style-type: none"> <li>Group agree that there is a need for an alert</li> <li>Ask Waikato pharmacist to write a draft alert (<b>Beth</b>)</li> </ul>

8.iv	Nifedipine long acting tablets	<ul style="list-style-type: none"> <li>• Pharmac considering funding another brand of long acting nifedipine tablets that are currently not registered and it is unknown yet if they are interchangeable with Adalat</li> <li>• Discussion about the need for a long acting nifedipine preparation</li> <li>• Do not want the same problem that we have with diltiazem and have too many non-interchangeable products listed</li> </ul>	<ul style="list-style-type: none"> <li>• Consider the number of preparations of the same product funded if they all have different release characteristics <b>(PHARMAC)</b></li> <li>• Respond to any consultation on this <b>(Beth)</b></li> </ul>
8.v	Summary of HDC incident	<ul style="list-style-type: none"> <li>• Discussed implications of the incident and system failures behind it</li> <li>• Need space for hand-written name on national drug chart</li> <li>• Nurses not taking responsibility for medicines they administer highlighted</li> <li>• Need access to drug charts at all times for all staff who might need them, ideal is for them to be at the end of the bed</li> <li>• Review of whole drug chart necessary when any new charting occurs</li> <li>• Need for team approach to care ie doctors and nurses on a ward round</li> <li>• Lack of clinical pharmacy service when incident occurred</li> <li>• Highlighted need for process to “look after” patients own medicines when they come into hospital</li> </ul>	<ul style="list-style-type: none"> <li>• Include space for hand written name on proposed national drug chart<b>(Beth)</b></li> <li>• Need to increase awareness of the group and medication safety within nursing organisations</li> <li>• Reinforce some of the messages that will be sent to all DHB’s in the HDC report in future newsletters etc</li> </ul>
5.i	Potassium	<ul style="list-style-type: none"> <li>• PHARMAC consultation closes 21/10/05</li> <li>• Submission from group making recommendations about increased range of concentrations required, generally and specific</li> </ul>	<ul style="list-style-type: none"> <li>• Send submission to PHARMAC <b>(Beth)</b></li> </ul>
5.ii	Warfarin	<ul style="list-style-type: none"> <li>• Some work on reliability of INR test strips done but not finished</li> <li>• Pack for practice nurses not finished</li> <li>• Have been sent a GP information sheet on warfarin management from Kowhai PHO and they are happy for it to be shared on website</li> </ul>	<ul style="list-style-type: none"> <li>• Check international literature re reliability etc of strips <b>(Beth)</b></li> <li>• Check if TGA have assessed them <b>(Beth)</b></li> <li>• Training pack <b>(Avril)</b></li> <li>• Put Kowhai GP warfarin information on website <b>(Beth)</b></li> </ul>
5.iii	Heparin	<ul style="list-style-type: none"> <li>• No progress on heparin in Auckland region yet</li> <li>• Discussed LMWH alert, both original and with changes suggested by group</li> </ul>	<ul style="list-style-type: none"> <li>• Work towards joint protocol and prescribing chart for heparin for Auckland region <b>(Beth)</b></li> <li>• Re-draft alert <b>(Peter)</b></li> </ul>
	Meeting dates for 2006	<ul style="list-style-type: none"> <li>• February 16<sup>th</sup> Wellington</li> <li>• April 20<sup>th</sup> Auckland</li> <li>• June 15<sup>th</sup> Wellington</li> <li>• August 17<sup>th</sup> Auckland</li> <li>• October 19<sup>th</sup> Wellington</li> <li>• December 14<sup>th</sup> Auckland</li> </ul>	
	<b>Date of next meeting</b>	<ul style="list-style-type: none"> <li>• <b>November 17<sup>th</sup> MOH Wellington</b></li> </ul>	